These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8841390)

  • 1. The clinical pharmacology of etoposide: an update.
    Joel S
    Cancer Treat Rev; 1996 May; 22(3):179-221. PubMed ID: 8841390
    [No Abstract]   [Full Text] [Related]  

  • 2. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Pfeiffer P; Rytter C; Madsen EL; Moeholt K; Hansen O; Bentzen S; Palshof T; Rose C
    J Natl Cancer Inst; 1997 Dec; 89(24):1892-3. PubMed ID: 9414178
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance to multiple agent chemotherapy including cisplatin after chronic low-dose oral etoposide administration in gestational choriocarcinoma.
    Okamoto T; Goto S
    Gynecol Obstet Invest; 2001; 52(2):139-41. PubMed ID: 11586044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
    Worth LL; Jaffe N; Benjamin RS; Papadopoulos NE; Patel S; Raymond AK; Jia SF; Rodriguez C; Gano J; Gianan MA; Kleinerman ES
    Clin Cancer Res; 1997 Oct; 3(10):1721-9. PubMed ID: 9815556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Etoposide: specificity of prolonged oral administration].
    Munck JN
    Bull Cancer; 1996 May; 83(5):352-60. PubMed ID: 8680087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Polyphenols as Modulators of Etoposide Anti-Cancer Activity.
    Kluska M; Woźniak K
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34202987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of etoposide on the pharmacokinetics of methotrexate in vivo.
    Paál K; Horváth J; Csáki C; Ferencz T; Schuler D; Borsi JD
    Anticancer Drugs; 1998 Oct; 9(9):765-72. PubMed ID: 9840721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Kitazawa J; Ito E; Arai K; Yokoyama M; Fukayama M; Imashuku S
    Med Pediatr Oncol; 2001 Aug; 37(2):153-4. PubMed ID: 11496359
    [No Abstract]   [Full Text] [Related]  

  • 10. Etoposide phosphate, the water soluble prodrug of etoposide.
    Witterland AH; Koks CH; Beijnen JH
    Pharm World Sci; 1996 Oct; 18(5):163-70. PubMed ID: 8933576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
    Southgate TD; Garside E; Margison GP; Fairbairn LJ
    J Gene Med; 2006 Aug; 8(8):972-9. PubMed ID: 16733832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of drug scheduling in cancer chemotherapy: etoposide as an example.
    Hande KR
    Stem Cells; 1996 Jan; 14(1):18-24. PubMed ID: 8820946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma.
    Nishimura S; Sato T; Ueda H; Ueda K
    J Clin Oncol; 2001 Nov; 19(21):4182-3. PubMed ID: 11689590
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary acute myelogenous leukemia following treatment with oral etoposide.
    Katato K; Flaherty L; Varterasian M
    Am J Hematol; 1996 Sep; 53(1):54-5. PubMed ID: 8813107
    [No Abstract]   [Full Text] [Related]  

  • 15. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diazepam enhances etoposide-induced cytotoxicity in U-87 MG human glioma cell line.
    Lavicka J; Sarisský M; Mirossay A; Sulla I; Mojzis J; Mirossay L
    Fundam Clin Pharmacol; 2001 Jun; 15(3):201-7. PubMed ID: 11468031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
    Chen CL; Fuscoe JC; Liu Q; Pui CH; Mahmoud HH; Relling MV
    J Natl Cancer Inst; 1996 Dec; 88(24):1840-7. PubMed ID: 8961974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy.
    Caruso R; Alesiani F; Latagliata R
    Haematologica; 1997; 82(1):126-7. PubMed ID: 9107103
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
    Ratain MJ; Schilsky RL; Wojack BR; Simon T; Senekjian EK; Vogelzang NJ
    J Natl Cancer Inst; 1988 Nov; 80(17):1412-6. PubMed ID: 3270508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related acute promyelocytic leukemia following etoposide-based chemotherapy in non-seminomatous germ cell tumor.
    Kumar TN; ; Gandhi LV; Raghunadharao D; Sadashivudu G
    J Postgrad Med; 2014; 60(1):84-5. PubMed ID: 24625948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.